Beth Kramer
I find it tragic that I must experience almost daily that cancer patients spend more time thinking about how many, and which, tablets they should take instead of dealing with personal changes.Alternative cancer treatment researcher Lothar Hirneise on change necessary for cancer patients It is genera...
Company Codes:NASDAQ-SMALL:BLRX, TelAviv:BLRX Clinical researchPhase IIAsia MORE ON THIS TOPIC Deals Roche Inks Potential $1.8B Deal With Flare to Target Transcription Factors in Cancer November 12, 2024 · 2 min read · Tri...
Tisotumab vedotin (TIVDAK®) has received full approval by the U.S. FDA for the treatment of adult patients with recurrent or metastatic cervical cancer (r/mCC) with disease progression on or after chemotherapy. Tisotumab vedotin in HNSCC is not approved in any country, including the U.S...
indicated in certain patients with advanced basal cell carcinoma (BCC), advanced CSCC and advanced non-small cell lung cancer (NSCLC), as well as in advanced cervical cancer in the European Union, Canada and Brazil. As of Ju...
33% Response Rate and 100% Disease Control Rate Observed in Patients Evaluated for Efficacy Complete Response of Non-Target Tumor Also Observed Platinum-Resistant Ovarian Cancer is a Devastating Serious Condition of Unme...
So for those who have ears to hear, I have some words of wisdom from 11 year old me. Here of late, I find myself surrounded by people who have been given positions of authority without the experience, education, knowledge, ability, and humility to handle it. Many people I love are be...
With CBD, several patients have been capable of finding comfort without suffering from adverse reactions for example opiate habit or paracetamol liver damage, when compared with classic method of therapy. The sleep-wake pattern is assisted We now have read a lot of information and researches, and...
(Another of her patients also had a baby and was being treated for cancer.) The doctor herself was pregnant. She was overwhelmed by imagining what it might be like to have a new baby and be diagnosed with cancer. She was struggling to “keep it together.”When we have a bad experience...
Median progression-free survival (mPFS) of 7.3 months overall Data support further investigation of zanidatamab plus chemotherapy as a novel therapeutic option for patients with HER2-positive metastatic breast cancer after three or more lines of prior therapy December...